While Hodgkin lymphoma is a relatively uncommon cancer, affecting an estimated 8,570 people in the US this year, its unique bimodal age pattern means it disproportionately strikes young adults and requires our focused attention.
Key Takeaways
- Estimated 8,570 new cases of Hodgkin lymphoma in the US in 2023
- Age-adjusted incidence rate of 2.8 per 100,000 in the US (2017-2021)
- Lifetime risk of developing Hodgkin lymphoma is 0.21% in the US
- EBV associated in 40-50% of cases overall
- HIV infection increases risk 10-fold
- Family history doubles risk in first-degree relatives
- Painless lymphadenopathy in 70-80% at presentation
- B symptoms (fever, night sweats, weight loss) in 40%
- Cervical/supraclavicular nodes involved in 60-80%
- Reed-Sternberg cells diagnostic in 95% biopsies
- Excisional biopsy preferred over core 90% accuracy
- CD15+, CD30+, CD45- in 85% classical HL
- 5-year overall survival 89.1%
- Stage I/II 5-year OS 92-95%
- Stage III/IV 5-year OS 80-85%
Hodgkin lymphoma is a treatable cancer with high survival rates across most ages.
Diagnosis
1Reed-Sternberg cells diagnostic in 95% biopsies
Verified2Excisional biopsy preferred over core 90% accuracy
Verified3CD15+, CD30+, CD45- in 85% classical HL
Verified4PET/CT for staging sensitivity 90-95%
Directional5Ann Arbor staging used in 100% cases
Single source6Bone marrow biopsy positive in 5-15% stage I/II
Verified7LDH elevated prognostic in 30%
Verified8EBV LMP1 detectable in 40%
Verified9CT chest/abdomen/pelvis standard 95%
Directional10Stage III/IV in 35% at diagnosis
Single source11Nodular sclerosis subtype 70%
Verified12Mixed cellularity 20-25%
Verified13Lymphocyte-rich 5%
Verified14NLPHL subtype 5%, indolent
Directional15IPS score 0-3 low risk 70%
Single source16Gallium scan historical sensitivity 90%
Verified17Flow cytometry not diagnostic <10% utility
Verified18Molecular testing for relapses 20%
Verified19Bulky disease >10cm in 20%
Directional20EBER-ISH positive confirms EBV 40%
Single sourceDiagnosis Interpretation
The path to a Hodgkin's diagnosis is a well-trodden but precise detective story, where the ghostly Reed-Sternberg cell is caught in 95% of excisional biopsies, confessing its identity with CD30 and CD15 in most cases, while PET/CT scans and Ann Arbor staging map its territory, revealing that while most patients present with early-stage, curable disease, a significant minority arrive with advanced or bulky illness, reminding us this lymphoma, though often conquered, demands serious respect.
Epidemiology
1Estimated 8,570 new cases of Hodgkin lymphoma in the US in 2023
Verified2Age-adjusted incidence rate of 2.8 per 100,000 in the US (2017-2021)
Verified3Lifetime risk of developing Hodgkin lymphoma is 0.21% in the US
Verified4Incidence rate 3.0 per 100,000 for males in the US
Directional5Incidence rate 2.5 per 100,000 for females in the US
Single source6Global incidence of 83,087 new cases in 2020
Verified7Highest incidence in Northern America at 3.4 per 100,000
Verified8Lowest incidence in Eastern Africa at 0.7 per 100,000
Verified9Bimodal age distribution with peaks at 15-34 and over 55 years
Directional10Median age at diagnosis 39 years
Single source11910 estimated deaths from Hodgkin lymphoma in the US in 2023
Verified12Prevalence of 37.4 per 100,000 in the US (2017-2021)
Verified13Incidence higher in Whites (3.1 per 100k) than Blacks (2.1 per 100k)
Verified14Annual incidence in Europe approximately 3 per 100,000
Directional15Incidence increased 2% per year from 2000-2020 in young adults
Single source160.5% of all new cancer cases in the US
Verified17Age-specific incidence peaks at 30-34 years (4.5 per 100k)
Verified185-year limited duration prevalence 31,470 cases in US
Verified19Incidence in Australia 3.2 per 100,000
Directional20UK incidence 3.1 per 100,000 (2017-2019)
Single source21Decreasing mortality trend 2.4% per year (2012-2021)
Verified2282,000 new cases worldwide annually
Verified23Higher incidence in developed countries
Verified24Hispanic incidence 4.0 per 100k highest among races
Directional25Incidence in children under 15: 0.5 per 100k
Single source2615-19 year olds have highest rate 5.2 per 100k
Verified27Global age-standardized mortality 0.6 per 100,000
Verified28US mortality rate 0.4 per 100,000
Verified29Incidence stable over last decade in US adults
Directional301.1% of lymphomas are Hodgkin type
Single sourceEpidemiology Interpretation
While these numbers paint a statistically modest portrait—a rarer cancer with a persistent if not particularly prominent presence, especially for the young—each new case number is a profound plot twist in a real human story.
Prognosis
15-year overall survival 89.1%
Verified2Stage I/II 5-year OS 92-95%
Verified3Stage III/IV 5-year OS 80-85%
Verified4ABVD chemo cure rate early stage 90%
Directional5Relapse rate 10-15% after first remission
Single source6IPS high risk >3 poor PFS 60% at 5y
Verified7Age >45 years HR 2.5 for mortality
Verified810-year OS 84%
Verified9NLPHL 10-year OS 95%
Directional10Advanced HL with B symptoms OS 75%
Single source11Stem cell transplant cure salvage 50%
Verified12Bulky disease impacts PFS 70% vs 85%
Verified13EBV+ HL worse OS HR 1.4
Verified14Pediatric HL 5y OS 98%
Directional15Elderly >60 5y OS 60-70%
Single source16HIV-HL 5y OS 70% with ART
Verified17Complete response rate ABVD 80%
Verified18Long-term survivors CV risk increased 2-7 fold
Verified19Secondary cancers 15-20% at 20y
Directional20Brentuximab vedotin PFS 75% relapsed
Single sourcePrognosis Interpretation
Hodgkin Lymphoma is a remarkably curable disease for most, but these encouraging survival statistics serve as a stark reminder that the real battle often shifts from the clinic to the heart, with a lifelong elevated risk of cardiovascular disease and secondary cancers for long-term survivors.
Risk Factors
1EBV associated in 40-50% of cases overall
Verified2HIV infection increases risk 10-fold
Verified3Family history doubles risk in first-degree relatives
Verified4EBV infection risk RR 4.1 in developing countries
Directional5Mononucleosis history increases risk 3-4 times
Single source6Smoking associated with 1.5-fold increased risk
Verified7Autoimmune diseases like RA increase risk 2.4-fold
Verified8Immunosuppression post-transplant RR 6.3
Verified9Male gender RR 1.2
Directional10Age 15-40 years higher relative risk
Single source11HLA genotype A1-B8-DR3 associated with risk
Verified12Obesity BMI>30 OR 1.5
Verified13Alcohol consumption protective OR 0.7
Verified14Socioeconomic status inverse association in young adults
Directional15HIV prevalence in HL patients up to 10% in some regions
Single source16Genetic syndromes like Klinefelter 3-5x risk
Verified17Celiac disease OR 6.9
Verified18Sjögren syndrome RR 5.8
Verified19EBV latency type II in 40% nodular sclerosis subtype
Directional20Twin studies show 80% heritability in monozygotic
Single source21Physical activity protective OR 0.8 per hour/week
Verified22Early menopause protective OR 0.6
Verified23Breastfeeding history OR 0.7
Verified24Asbestos exposure weak association OR 1.3
DirectionalRisk Factors Interpretation
While a perfect storm of viral ghosts, family ties, weakened immunity, and lifestyle factors conspire to raise the risk of Hodgkin Lymphoma, the body's own history—like past pregnancies or a regular drink—can sometimes offer a surprising shield.
Symptoms
1Painless lymphadenopathy in 70-80% at presentation
Verified2B symptoms (fever, night sweats, weight loss) in 40%
Verified3Cervical/supraclavicular nodes involved in 60-80%
Verified4Mediastinal mass in 50-60% of cases
Directional5Pruritus in 10-30%
Single source6Fatigue reported in 30%
Verified7Cough/dyspnea from mediastinal involvement 25%
Verified8Pel-Ebstein fever cyclical in 20-30%
Verified9Splenomegaly in 20-30%
Directional10Alcohol-induced pain in nodes 5-10%
Single source11Anemia in 30% at diagnosis
Verified12Elevated ESR (>50 mm/h) in 40%
Verified13Back pain from retroperitoneal disease 10%
Verified14Facial edema superior vena cava syndrome 5%
Directional15Generalized weakness 25%
Single source16Night sweats drenching in 20%
Verified17Unintentional weight loss >10% in 30%
Verified18Axillary nodes 20-30%
Verified19Inguinal nodes less common 5-10%
Directional20Paraneoplastic syndromes rare <5%
Single sourceSymptoms Interpretation
Hodgkin's Lymphoma is a master of disguise, most often introducing itself as a suspicious but painless lump in the neck, yet it keeps a whole menu of systemic annoyances—from drenching night sweats to puzzling alcohol-induced pain—in its back pocket to complicate the plot.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2SEERseer.cancer.govVisit source
- Reference 3GCOgco.iarc.who.intVisit source
- Reference 4CANCERcancer.govVisit source
- Reference 5NCBIncbi.nlm.nih.govVisit source
- Reference 6PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8CANCERRESEARCHUKcancerresearchuk.orgVisit source